The amycretin pill from Novo Nordisk is making headlines in 2025 after impressive phase 2 trial results released on November 25. This once-daily oral medication delivered up to 14.5% average weight loss while significantly improving blood sugar control in adults with type 2 diabetes — offering a true “double win” over existing injectable treatments like Ozempic and Wegovy. For patients seeking a convenient pill instead of weekly shots, amycretin could become the next breakthrough in obesity and diabetes management.
How the Amycretin Pill Targets GLP-1 and Amylin Simultaneously
Amycretin isn’t just another weight loss pill, it’s a “unimolecular” agonist, meaning a single molecule designed to mimic the effects of two key gut hormones: glucagon-like peptide-1 (GLP-1) and amylin. GLP-1, the star of drugs like semaglutide (the active ingredient in Ozempic), works by signaling the brain to reduce appetite, slow gastric emptying, and boost insulin release after meals. Amylin, produced by the pancreas, complements this by further suppressing hunger and fine-tuning blood sugar regulation.
By targeting both receptors at once, amycretin aims for amplified effects with potentially fewer doses. In this trial, it was tested as a once-daily oral formulation (alongside a once-weekly subcutaneous version), making it a user-friendly contender in a market dominated by needles.
Breaking Down the Trial Results: Weight Loss Meets Glycemic Control
The phase 2 study, the first to evaluate amycretin specifically in 448 adults with type 2 diabetes whose condition wasn’t well-managed by standard treatments like metformin (with or without an SGLT2 inhibitor), spanned 36 weeks. Participants were randomized to receive either oral or injectable amycretin at varying doses or a placebo.
The results were compelling:
- Weight Loss: Participants on the highest oral dose achieved an average reduction of up to 14.5% of their body weight by week 36—far surpassing the modest changes seen with placebo. For context, this edges out the 13.1% loss observed in a smaller, earlier trial of the oral version after just 12 weeks. The injectable form showed even stronger potential in prior studies, with up to 22% loss at 36 weeks.
- Blood Sugar Mastery: The drug hit its primary goal, delivering statistically significant drops in HbA1c (a key measure of long-term blood glucose control). Remarkably, up to 89.1% of participants on higher doses reached HbA1c levels below 7%—a threshold that significantly lowers risks for complications like heart disease and nerve damage.
These dose-dependent improvements underscore amycretin’s potential as a “best-in-class” therapy, as described by Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange, MD, PhD. “The data further validate the potential best-in-class profile of amycretin,” Lange stated, highlighting its efficacy in a population where obesity and diabetes often intersect.
Safety Profile: Familiar but Manageable
No drug is without hurdles, and amycretin follows the playbook of its GLP-1 predecessors. The most common side effects were mild to moderate gastrointestinal issues, such as nausea, vomiting, and diarrhea—reported in line with what clinicians see from incretin-based therapies. These typically peaked during dose escalation and waned over time, with no new red flags emerging.
Overall, the safety data supports amycretin’s tolerability, paving the way for broader testing. Novo Nordisk plans to launch phase 3 trials in 2026, expanding to larger groups with obesity (with or without diabetes) to confirm these benefits and refine dosing.
Why This Matters: A Pill for the People
Obesity affects over 1 billion people worldwide, often fueling type 2 diabetes and related conditions that claim millions of lives annually. Current GLP-1 drugs have revolutionized care but come with barriers: weekly injections, high costs, and supply shortages. Amycretin’s oral format could democratize access, especially for those needle-averse or in resource-limited settings.
The “double win” here—tackling weight and glucose simultaneously—addresses a critical gap. As experts like Tricia Tan, professor of metabolic medicine at Imperial College London, note in related commentary, evolving obesity treatments now prioritize not just pounds lost but risks reduced, like cardiovascular events. If phase 3 pans out, amycretin could join or surpass semaglutide in efficacy while offering daily convenience.
Novo’s stock surged nearly 5% on the news, reflecting investor optimism in reclaiming market dominance amid competition from Eli Lilly’s Mounjaro. Yet, the real excitement lies in its promise for patients: a simpler path to healthier weights and stable sugars.
Looking Ahead: From Promise to Prescription
As Novo Nordisk accelerates amycretin toward potential approval, the focus shifts to real-world impact. Will this pill maintain its edge in diverse populations? How will it stack up against head-to-head rivals? For now, these results signal a brighter horizon for metabolic health—one pill at a time.
If you’re managing weight or diabetes, consult your healthcare provider about emerging options. The future of treatment is swallowing progress, not injecting it.
